Debra Richardson

Professor and Section Chief

University of Kansas Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Debra Richardson is a Professor and Section Chief at OU Health Stephenson Cancer Center in the United States. Her research focuses on innovative treatment strategies for gynecological cancers, particularly in the areas of chemoradiation and immunotherapy. Recent publications include studies on the efficacy of gene therapy in ovarian cancer and the incorporation of triapine in chemoradiation protocols for cervical cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Susumu Shimoyama

UNITED STATES

View details

Devalingam Mahalingam

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Sarah Lynam

Assistant Professor - Gynecologic Oncology

University Hospital

UNITED STATES

View details

David Warshal

Head, Division of Gynecologic Oncology

Cooper University Health Care

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Debra Richardson

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer

A trial of radiolabeled antibody yttrium‐90–FF‐21101 for the treatment of advanced ovarian and other cancers

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.

Collaborators (4)

Susumu Shimoyama

Devalingam Mahalingam

Sarah Lynam

David Warshal

Make your next move.